Editorial Comment
Editorial Comment to Infectious aortic aneurysms occurring 1 year after bacillus Calmette–Guérin bladder instillation therapy
First published: 13 November 2014
No abstract is available for this article.
References
- 1
Koya MP,
Simon MA,
Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J. Urol. 2006; 175: 2004–2010.
- 2
Saint F,
Irani J,
Patard JJ et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 883–888.
- 3
Sylvester RJ,
van der Meijden APM,
Oosterlinck W et al. The side effects of Bacillus Calmette-Guerin in the treatment of Ta-T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial. Eur. Urol. 2003; 44: 423–428.
- 4
Brausi M,
Oddens J,
Sylvester R et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur. Urol. 2014; 65: 69–76.
- 5
Akita H,
Okamura T,
Nakane A,
Kobayashi T,
Yamada K,
Tanaka Y. Infectious aortic aneurysms occurring 1 year after bacillus Calmette-Guérin bladder instillation therapy. Int. J. Urol. 2015; 22: 234–5.
